{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:48:51Z","timestamp":1789908531744,"version":"4.0.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,2,29]],"date-time":"2016-02-29T00:00:00Z","timestamp":1456704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1038\/leu.2016.42","type":"journal-article","created":{"date-parts":[[2016,2,29]],"date-time":"2016-02-29T07:56:38Z","timestamp":1456732598000},"page":"1273-1281","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia"],"prefix":"10.1038","volume":"30","author":[{"given":"C M","family":"Lucas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Milani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Butterworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Carmell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L J","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R E","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G M","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Varadarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,29]]},"reference":[{"key":"BFleu201642_CR1","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1126\/science.3460176","volume":"233","author":"Y Ben-Neriah","year":"1986","unstructured":"Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D . The chronic myelogenous leukemia-specific P210 protein is the product of the bcr\/abl hybrid gene. Science 1986; 233: 212\u2013214.","journal-title":"Science"},{"key":"BFleu201642_CR2","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1038\/leu.2008.225","volume":"22","author":"CM Lucas","year":"2008","unstructured":"Lucas CM, Wang L, Austin GM, Knight K, Watmough SJ, Shwe KH et al. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia 2008; 22: 1963\u20131966.","journal-title":"Leukemia"},{"key":"BFleu201642_CR3","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","volume":"26","author":"H de Lavallade","year":"2008","unstructured":"de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008; 26: 3358\u20133363.","journal-title":"J Clin Oncol"},{"key":"BFleu201642_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","volume":"8","author":"P Neviani","year":"2005","unstructured":"Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein. Cancer Cell 2005; 8: 355\u2013368.","journal-title":"Cancer Cell"},{"key":"BFleu201642_CR5","doi-asserted-by":"publisher","first-page":"6660","DOI":"10.1182\/blood-2010-08-304477","volume":"117","author":"CM Lucas","year":"2011","unstructured":"Lucas CM, Harris RJ, Giannoudis A, Copland M, Slupsky JR, Clark RE . Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood 2011; 117: 6660\u20136668.","journal-title":"Blood"},{"key":"BFleu201642_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cell.2007.04.044","volume":"130","author":"MR Junttila","year":"2007","unstructured":"Junttila MR, Puustinen P, Niemel\u00e4 M, Ahola R, Arnold H, B\u00f6ttzauw T et al. CIP2A inhibits PP2A in human malignancies. Cell 2007; 130: 51\u201362.","journal-title":"Cell"},{"key":"BFleu201642_CR7","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/jnci\/djp103","volume":"101","author":"A Khanna","year":"2009","unstructured":"Khanna A, B\u00f6ckelman C, Hemmes A, Junttila MR, Wiksten J-P, Lundin M et al. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst 2009; 101: 793\u2013805.","journal-title":"J Natl Cancer Inst"},{"key":"BFleu201642_CR8","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.3324\/haematol.2014.115691","volume":"100","author":"CM Lucas","year":"2015","unstructured":"Lucas CM, Harris RJ, Giannoudis A, Clark RE . c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia. Haematologica 2015; 100: e179\u2013e182.","journal-title":"Haematologica"},{"key":"BFleu201642_CR9","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/ncb1499","volume":"8","author":"H Kim","year":"2006","unstructured":"Kim H, Rafiuddin-Shah M, Tu H-C, Jeffers JR, Zambetti GP, Hsieh JJ-D et al. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 2006; 8: 1348\u20131358.","journal-title":"Nat Cell Biol"},{"key":"BFleu201642_CR10","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","volume":"9","author":"M Certo","year":"2006","unstructured":"Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006; 9: 351\u2013365.","journal-title":"Cancer Cell"},{"key":"BFleu201642_CR11","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/cr.2010.149","volume":"21","author":"B Ku","year":"2011","unstructured":"Ku B, Liang C, Jung JU, Oh B-H . Evidence that inhibition of BAX activation by BCL-2 involves its tight and preferential interaction with the BH3 domain of BAX. Cell Res 2011; 21: 627\u2013641.","journal-title":"Cell Res"},{"key":"BFleu201642_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1006\/mcbr.2000.0231","volume":"3","author":"RP de Groot","year":"2000","unstructured":"de Groot RP, Raaijmakers JA, Lammers JW, Koenderman L . STAT5-dependent CyclinD1 and Bcl-xL expression in Bcr-Abl-transformed cells. Mol Cell Biol Res Commun 2000; 3: 299\u2013305.","journal-title":"Mol Cell Biol Res Commun"},{"key":"BFleu201642_CR13","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1084\/jem.191.6.977","volume":"191","author":"M Horita","year":"2000","unstructured":"Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, Benet I et al. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med 2000; 191: 977\u2013984.","journal-title":"J Exp Med"},{"key":"BFleu201642_CR14","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1128\/MCB.20.4.1179-1186.2000","volume":"20","author":"MS Neshat","year":"2000","unstructured":"Neshat MS, Raitano AB, Wang HG, Reed JC, Sawyers CL . The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Mol Cell Biol 2000; 20: 1179\u20131186.","journal-title":"Mol Cell Biol"},{"key":"BFleu201642_CR15","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/blood.V96.2.676","volume":"96","author":"P Salomoni","year":"2000","unstructured":"Salomoni P, Condorelli F, Sweeney SM, Calabretta B . Versatility of BCR\/ABL-expressing leukemic cells in circumventing proapoptotic BAD effects. Blood 2000; 96: 676\u2013684.","journal-title":"Blood"},{"key":"BFleu201642_CR16","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/annonc\/mdv110","volume":"26","author":"K Korfi","year":"2015","unstructured":"Korfi K, Mandal A, Furney SJ, Wiseman D, Somervaille TCP, Marais R . A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia. Ann Oncol 2015; 26: 1180\u20131187.","journal-title":"Ann Oncol"},{"key":"BFleu201642_CR17","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/leu.2011.285","volume":"26","author":"DH Mak","year":"2012","unstructured":"Mak DH, Wang R-Y, Schober WD, Konopleva M, Cortes J, Kantarjian H et al. Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors. Leukemia 2012; 26: 788\u2013794.","journal-title":"Leukemia"},{"key":"BFleu201642_CR18","doi-asserted-by":"publisher","first-page":"9033","DOI":"10.18632\/oncotarget.1925","volume":"5","author":"TK Ko","year":"2014","unstructured":"Ko TK, Chuah CTH, Huang JWJ, Ng K-P, Ong ST . The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors. Oncotarget 2014; 5: 9033\u20139038.","journal-title":"Oncotarget"},{"key":"BFleu201642_CR19","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1038\/leu.2013.151","volume":"27","author":"JG Harb","year":"2013","unstructured":"Harb JG, Neviani P, Chyla BJ, Ellis JJ, Ferenchak GJ, Oaks JJ et al. Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target. Leukemia 2013; 27: 1996\u20132005.","journal-title":"Leukemia"},{"key":"BFleu201642_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ejps.2015.01.003","volume":"70","author":"T Song","year":"2015","unstructured":"Song T, Chai G, Liu Y, Xie M, Chen Q, Yu X et al. Mechanism of synergy of BH3 mimetics and paclitaxel in chronic myeloid leukemia cells: Mcl-1 inhibition. Eur J Pharm Sci 2015; 70: 64\u201371.","journal-title":"Eur J Pharm Sci"},{"key":"BFleu201642_CR21","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","volume":"68","author":"C Tse","year":"2008","unstructured":"Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421\u20133428.","journal-title":"Cancer Res"},{"key":"BFleu201642_CR22","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19: 202\u2013208.","journal-title":"Nat Med"},{"key":"BFleu201642_CR23","doi-asserted-by":"publisher","first-page":"279ra40","DOI":"10.1126\/scitranslmed.aaa4642","volume":"7","author":"JD Leverson","year":"2015","unstructured":"Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med 2015; 7: 279ra40.","journal-title":"Sci Transl Med"},{"key":"BFleu201642_CR24","doi-asserted-by":"publisher","first-page":"e1590","DOI":"10.1038\/cddis.2014.561","volume":"6","author":"JD Leverson","year":"2015","unstructured":"Leverson JD, Zhang H, Chen J, Tahir SK, Phillips DC, Xue J et al. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis 2015; 6: e1590.","journal-title":"Cell Death Dis"},{"key":"BFleu201642_CR25","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ymeth.2013.04.006","volume":"61","author":"J Ryan","year":"2013","unstructured":"Ryan J, Letai A . BH3 profiling in whole cells by fluorimeter or FACS. Methods 2013; 61: 156\u2013164.","journal-title":"Methods"},{"key":"BFleu201642_CR26","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1182\/blood-2008-08-173310","volume":"113","author":"M Vogler","year":"2009","unstructured":"Vogler M, Butterworth M, Majid A, Walewska RJ, Sun X-M, Dyer MJS et al. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 2009; 113: 4403\u20134413.","journal-title":"Blood"},{"key":"BFleu201642_CR27","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1038\/leu.2015.71","volume":"29","author":"CM Lucas","year":"2015","unstructured":"Lucas CM, Harris RJ, Holcroft AK, Scott LJ, Carmell N, McDonald E et al. Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients. Leukemia 2015; 29: 1514\u20131523.","journal-title":"Leukemia"},{"key":"BFleu201642_CR28","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.cell.2015.01.042","volume":"160","author":"J Montero","year":"2015","unstructured":"Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D et al. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell 2015; 160: 977\u2013989.","journal-title":"Cell"},{"key":"BFleu201642_CR29","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1182\/blood-2012-11-466037","volume":"121","author":"P Neelakantan","year":"2013","unstructured":"Neelakantan P, Gerrard G, Lucas C, Milojkovic D, May P, Wang L et al. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood 2013; 121: 2739\u20132742.","journal-title":"Blood"},{"key":"BFleu201642_CR30","doi-asserted-by":"crossref","unstructured":"O'Brien S, Hedgley C, Foroni L, Apperley J, Osborne W, Zwingers T et al. SPIRIT 2: an NCRI randomised study comparing dasatinib with imatinib in patients with newly diagnosed chronic myeloid leukaemia\u22122 year follow up. Accepted for the European Haematology Association Annual Meeting, : Vienna, June 2015 (oral presentation).","DOI":"10.1182\/blood.V124.21.517.517"},{"key":"BFleu201642_CR31","unstructured":"Hughes TP, Larson RA, Kim D-W, Issaragrisil S, le Coutre PD, Lobo C et al. Efficacy and safety of nilotinib (NIL) vs. imatinib (IM) in patients with newly diagnosed chronic myeloid leukaemia in chronic phase (CML-CP): 6-year follow-up of ENESTnd. Accepted for the European Haematology Association Annual Meeting: Vienna, Austria, June 2015 (poster presentation)."},{"key":"BFleu201642_CR32","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1046\/j.0902-4441.2003.00201.x","volume":"72","author":"S Guti\u00e9rrez-Castellanos","year":"2004","unstructured":"Guti\u00e9rrez-Castellanos S, Cruz M, Rabelo L, God\u00ednez R, Reyes-Maldonado E, Riebeling-Navarro C . Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients. Eur J Haematol 2004; 72: 231\u2013238.","journal-title":"Eur J Haematol"},{"key":"BFleu201642_CR33","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1158\/1535-7163.MCT-08-0314","volume":"7","author":"NN Bewry","year":"2008","unstructured":"Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, Hazlehurst LA . Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther 2008; 7: 3169\u20133175.","journal-title":"Mol Cancer Ther"},{"key":"BFleu201642_CR34","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1038\/sj.onc.1201664","volume":"16","author":"GP Amarante-Mendes","year":"1998","unstructured":"Amarante-Mendes GP, McGahon AJ, Nishioka WK, Afar DE, Witte ON, Green DR . Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene 1998; 16: 1383\u20131390.","journal-title":"Oncogene"},{"key":"BFleu201642_CR35","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.scr.2011.08.002","volume":"8","author":"H Bai","year":"2012","unstructured":"Bai H, Chen K, Gao Y-X, Arzigian M, Xie Y-L, Malcosky C et al. Bcl-xL enhances single-cell survival and expansion of human embryonic stem cells without affecting self-renewal. Stem Cell Res 2012; 8: 26\u201337.","journal-title":"Stem Cell Res"},{"key":"BFleu201642_CR36","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1038\/cdd.2014.105","volume":"21","author":"A Zeuner","year":"2014","unstructured":"Zeuner A, Francescangeli F, Contavalli P, Zapparelli G, Apuzzo T, Eramo A et al. Elimination of quiescent\/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer. Cell Death Differ 2014; 21: 1877\u20131888.","journal-title":"Cell Death Differ"},{"key":"BFleu201642_CR37","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1172\/JCI35721","volume":"121","author":"AS Corbin","year":"2011","unstructured":"Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ . Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011; 121: 396\u2013409.","journal-title":"J Clin Invest"},{"key":"BFleu201642_CR38","doi-asserted-by":"publisher","first-page":"7145","DOI":"10.1182\/blood-2011-03-344812","volume":"117","author":"M Vogler","year":"2011","unstructured":"Vogler M, Hamali HA, Sun X-M, Bampton ETW, Dinsdale D, Snowden RT et al. BCL2\/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation. Blood 2011; 117: 7145\u20137154.","journal-title":"Blood"},{"key":"BFleu201642_CR39","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/leu.2010.294","volume":"25","author":"I Crist\u00f3bal","year":"2011","unstructured":"Crist\u00f3bal I, Garcia-Orti L, Cirauqui C, Alonso MM, Calasanz MJ, Odero MD . PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia 2011; 25: 606\u2013614.","journal-title":"Leukemia"},{"key":"BFleu201642_CR40","doi-asserted-by":"publisher","first-page":"5092","DOI":"10.1158\/1078-0432.CCR-08-3283","volume":"15","author":"C Come","year":"2009","unstructured":"Come C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X et al. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res 2009; 15: 5092\u20135100.","journal-title":"Clin Cancer Res"},{"key":"BFleu201642_CR41","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3233\/CBM-2011-0220","volume":"8","author":"LP Huang","year":"2010","unstructured":"Huang LP, Adelson ME, Mordechai E, Trama JP . CIP2A expression is elevated in cervical cancer. Cancer Biomark 2010; 8: 309\u2013317.","journal-title":"Cancer Biomark"},{"key":"BFleu201642_CR42","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/cam4.15","volume":"1","author":"LP Huang","year":"2012","unstructured":"Huang LP, Savoly D, Sidi AA, Adelson ME, Mordechai E, Trama JP . CIP2A protein expression in high-grade, high-stage bladder cancer. Cancer Med 2012; 1: 76\u201381.","journal-title":"Cancer Med"},{"key":"BFleu201642_CR43","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s11605-012-1828-3","volume":"16","author":"H-W Teng","year":"2012","unstructured":"Teng H-W, Yang S-H, Lin J-K, Chen W-S, Lin T-C, Jiang J-K et al. CIP2A is a predictor of poor prognosis in colon cancer. J Gastrointest Surg 2012; 16: 1037\u20131047.","journal-title":"J Gastrointest Surg"},{"key":"BFleu201642_CR44","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/PDM.0b013e318249fd8b","volume":"21","author":"H He","year":"2012","unstructured":"He H, Wu G, Li W, Cao Y, Liu Y . CIP2A is highly expressed in hepatocellular carcinoma and predicts poor prognosis. Diagn Mol Pathol 2012; 21: 143\u2013149.","journal-title":"Diagn Mol Pathol"},{"key":"BFleu201642_CR45","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1245\/s10434-010-1313-8","volume":"18","author":"Q-Z Dong","year":"2011","unstructured":"Dong Q-Z, Wang Y, Dong X-J, Li Z-X, Tang Z-P, Cui Q-Z et al. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol 2011; 18: 857\u2013865.","journal-title":"Ann Surg Oncol"},{"key":"BFleu201642_CR46","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.18632\/oncotarget.2127","volume":"5","author":"P De","year":"2014","unstructured":"De P, Carlson J, Leyland-Jones B, Dey N . Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands. Oncotarget 2014; 5: 4581\u20134602.","journal-title":"Oncotarget"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu201642.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu201642","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu201642.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:06:55Z","timestamp":1684433215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,29]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["BFleu201642"],"URL":"https:\/\/doi.org\/10.1038\/leu.2016.42","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,29]]},"assertion":[{"value":"28 August 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 February 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"REC has received research funding from Novartis, Bristol Myers Squibb and Pfizer and is a member of the speakers\u2019 bureau for Novartis. All authors report no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}